MAPT and Alzheimer disease: In a Phase 1b clinical study, the MAPT-ASO candidate BIIB080 demonstrated a dose-dependent and sustained reduction in cerebrospinal fluid (CSF) total tau and phosphorylated tau (p-tau) and is currently being further evaluated in a Phase 2 trial, thus highlighting the clinical potential of MAPT-ASOs in treating AD [15,16].